96 related articles for article (PubMed ID: 9748126)
21. Dendritic cell targeting vaccine for HPV-associated cancer.
Yin W; Duluc D; Joo H; Oh S
Cancer Cell Microenviron; 2016; 3(4):. PubMed ID: 28133621
[TBL] [Abstract][Full Text] [Related]
22. Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.
Kim S; Chung HW; Kong HY; Lim JB
Yonsei Med J; 2017 Jan; 58(1):43-50. PubMed ID: 27873494
[TBL] [Abstract][Full Text] [Related]
23. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Skeate JG; Woodham AW; Einstein MH; Da Silva DM; Kast WM
Hum Vaccin Immunother; 2016 Jun; 12(6):1418-29. PubMed ID: 26835746
[TBL] [Abstract][Full Text] [Related]
24. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Vaccine Strategies against Human Papillomavirus.
Khallouf H; Grabowska AK; Riemer AB
Vaccines (Basel); 2014 Jun; 2(2):422-62. PubMed ID: 26344626
[TBL] [Abstract][Full Text] [Related]
26. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
Stevanović S; Draper LM; Langhan MM; Campbell TE; Kwong ML; Wunderlich JR; Dudley ME; Yang JC; Sherry RM; Kammula US; Restifo NP; Rosenberg SA; Hinrichs CS
J Clin Oncol; 2015 May; 33(14):1543-50. PubMed ID: 25823737
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells.
Shen KY; Song YC; Chen IH; Leng CH; Chen HW; Li HJ; Chong P; Liu SJ
J Immunol; 2014 May; 192(9):4233-41. PubMed ID: 24683188
[TBL] [Abstract][Full Text] [Related]
28. Immunologic treatments for precancerous lesions and uterine cervical cancer.
Vici P; Mariani L; Pizzuti L; Sergi D; Di Lauro L; Vizza E; Tomao F; Tomao S; Cavallotti C; Paolini F; Venuti A
J Exp Clin Cancer Res; 2014 Mar; 33(1):29. PubMed ID: 24667138
[TBL] [Abstract][Full Text] [Related]
29. Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.
Knoff J; Yang B; Hung CF; Wu TC
Curr Obstet Gynecol Rep; 2014 Mar; 3(1):18-32. PubMed ID: 24533233
[TBL] [Abstract][Full Text] [Related]
30. Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers.
Nayereh KG; Khadem G
Iran J Basic Med Sci; 2012 Jan; 15(1):585-601. PubMed ID: 23493151
[TBL] [Abstract][Full Text] [Related]
31. Emerging human papillomavirus vaccines.
Ma B; Maraj B; Tran NP; Knoff J; Chen A; Alvarez RD; Hung CF; Wu TC
Expert Opin Emerg Drugs; 2012 Dec; 17(4):469-92. PubMed ID: 23163511
[TBL] [Abstract][Full Text] [Related]
32. Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.
Solares AM; Baladron I; Ramos T; Valenzuela C; Borbon Z; Fanjull S; Gonzalez L; Castillo D; Esmir J; Granadillo M; Batte A; Cintado A; Ale M; Fernandez de Cossio ME; Ferrer A; Torrens I; Lopez-Saura P
ISRN Obstet Gynecol; 2011; 2011():292951. PubMed ID: 21748025
[TBL] [Abstract][Full Text] [Related]
33. TLR-based immune adjuvants.
Steinhagen F; Kinjo T; Bode C; Klinman DM
Vaccine; 2011 Apr; 29(17):3341-55. PubMed ID: 20713100
[TBL] [Abstract][Full Text] [Related]
34. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.
Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL
J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877
[TBL] [Abstract][Full Text] [Related]
35. [Prophylactic and therapeutic vaccines against human papilloma virus].
Albers AE; Hoffmann TK; Klussmann JP; Kaufmann AM
HNO; 2010 Aug; 58(8):778-90. PubMed ID: 20544168
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for cervical cancer: Research status and clinical potential.
Su JH; Wu A; Scotney E; Ma B; Monie A; Hung CF; Wu TC
BioDrugs; 2010 Apr; 24(2):109-29. PubMed ID: 20199126
[TBL] [Abstract][Full Text] [Related]
37. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.
Black M; Trent A; Tirrell M; Olive C
Expert Rev Vaccines; 2010 Feb; 9(2):157-73. PubMed ID: 20109027
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic vaccines against human papillomavirus and cervical cancer.
Cid-Arregui A
Open Virol J; 2009 Oct; 3():67-83. PubMed ID: 19915722
[TBL] [Abstract][Full Text] [Related]
39. HPV as a model for the development of prophylactic and therapeutic cancer vaccines.
Samara RN; Khleif SN
Curr Mol Med; 2009 Aug; 9(6):766-73. PubMed ID: 19689303
[TBL] [Abstract][Full Text] [Related]
40. The future of vaccines for cervical cancer.
Huh WK; Roden RB
Gynecol Oncol; 2008 May; 109(2 Suppl):S48-56. PubMed ID: 18482559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
